Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,715 across all filing types
Latest filing 2022-05-20 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
中天国富证券有限公司关于美康生物科技股份有限公司使用部分闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed opinion and verification report from a sponsoring securities company regarding the use of idle raised funds by a listed company for cash management. It includes regulatory references, investment limits, risk controls, and approvals from the board, supervisory committee, independent directors, and the sponsor. It is not a full financial report but a regulatory compliance and verification document related to the use of raised funds. The document length is about 4000 characters, which is relatively short but contains substantive content about the use of funds and regulatory compliance. It is not an announcement of a report publication but a formal verification opinion. This fits best under the category of Regulatory Filings (RNS), as it is a regulatory compliance document that does not fit into other specific categories like Annual Report, Capital Update, or Audit Report.
2022-05-20 Chinese
2021年年度股东大会决议公告
AGM Information Classification · 95% confidence The document is titled as a 2021 Annual General Meeting (AGM) resolution announcement for 美康生物科技股份有限公司. It details the meeting date, attendance, voting results on various proposals including the 2021 annual report, financial statements, profit distribution plan, and amendments to company bylaws. It also includes legal opinions confirming the validity of the meeting and voting process. The content is focused on the resolutions passed at the AGM rather than the full annual report or financial statements themselves. The document length is about 5737 characters, which is consistent with a detailed AGM resolution announcement rather than a full annual report. Therefore, this document fits the category of AGM Information (AGM-R).
2022-05-17 Chinese
国浩律师（杭州）事务所关于美康生物2021年年度股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2021 Annual General Meeting (AGM) of Meikang Biotechnology Co., Ltd. It details the convening, attendance, agenda, voting procedures, and results of the AGM. The document does not contain the actual annual report or financial statements but focuses on the legality and validity of the AGM process and voting outcomes. This type of document is typically associated with the declaration of voting results and voting rights announcements following an AGM. The document length is 7,955 characters, which is substantial and contains detailed voting results, supporting classification as a Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-05-17 Chinese
关于召开2021年度股东大会的提示性公告
AGM Information Classification · 100% confidence The document is a detailed announcement regarding the convening of the 2021 Annual General Meeting (AGM) of 美康生物科技股份有限公司. It includes information about the meeting date, voting procedures (both online and onsite), agenda items to be voted on, registration details, and attachments such as proxy forms and voting instructions. The document does not contain the actual annual report or financial statements but rather serves as a notice and instructions for shareholders to participate in the AGM. It is not a report publication announcement since it is lengthy and detailed, focusing on the meeting logistics and agenda. Therefore, the document fits the category of AGM Information (AGM-R).
2022-05-12 Chinese
2022年第一季度报告披露提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (499 characters) about the disclosure of the company's 2022 first quarter report. It states that the full quarterly report has been published on the official disclosure website and invites investors to review it. There is no substantive financial data or detailed analysis within this text itself, only a notification of the report's availability. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA), not the actual Interim/Quarterly Report (IR).
2022-04-26 Chinese
董事、监事和高级管理人员对公司2022年第一季度报告的书面确认意见
Regulatory Filings Classification · 95% confidence The document is a written confirmation opinion from the company's directors, supervisors, and senior management regarding the company's 2022 first quarter report. It states that they have reviewed the 2022 first quarter report and confirm the accuracy and completeness of the information disclosed. The document itself does not contain the actual financial data or detailed report but is a certification or attestation related to the interim/quarterly report. According to the Certification Rule, such officer certifications or confirmations referencing a report should be classified as Regulatory Filings (RNS), not as the interim report itself (IR). The document length is short (637 characters), and it is primarily a confirmation letter rather than the report itself.
2022-04-26 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.